Shattuck Labs, Inc. Operating Income
Shattuck Labs, Inc. (STTK) reported Operating Income of -$16.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-11
- Shattuck Labs, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$16.16M.
- Shattuck Labs, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$15.54M.
- Shattuck Labs, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$13.37M.
- Shattuck Labs, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$10.72M.
- Shattuck Labs, Inc. operating income (loss) for fiscal 2025 was -$51.51M.
- Shattuck Labs, Inc. operating income (loss) for fiscal 2024 was -$80.57M.
- Shattuck Labs, Inc. operating income (loss) for fiscal 2023 was -$91.96M.
- Shattuck Labs, Inc. operating income (loss) for fiscal 2022 was -$103.33M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$16.16M 10-Q · filed 2026-08-11 | -$31.70M 10-Q · filed 2026-08-11 | -$45.07M derived: sum of 3 quarters · filed 2026-08-11 | -$55.79M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$15.54M 10-Q · filed 2026-05-07 | -$28.92M derived: sum of 2 quarters · filed 2026-05-07 | -$39.63M derived: sum of 3 quarters · filed 2026-05-07 | -$52.66M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$13.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$24.09M derived: sum of 2 quarters · filed 2026-03-05 | -$37.12M derived: sum of 3 quarters · filed 2026-08-11 | -$51.51M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$10.72M 10-Q · filed 2025-11-06 | -$23.75M derived: sum of 2 quarters · filed 2026-08-11 | -$38.14M 10-Q · filed 2025-11-06 | -$57.78M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$13.03M 10-Q · filed 2026-08-11 | -$27.42M 10-Q · filed 2026-08-11 | -$47.06M derived: sum of 3 quarters · filed 2026-08-11 | -$64.98M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$14.39M 10-Q · filed 2026-05-07 | -$34.03M derived: sum of 2 quarters · filed 2026-05-07 | -$51.95M derived: sum of 3 quarters · filed 2026-05-07 | -$74.91M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$19.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$37.56M derived: sum of 2 quarters · filed 2026-03-05 | -$60.52M derived: sum of 3 quarters · filed 2026-03-05 | -$80.57M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$17.92M 10-Q · filed 2025-11-06 | -$40.88M derived: sum of 2 quarters · filed 2025-11-06 | -$60.93M 10-Q · filed 2025-11-06 | -$79.88M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$22.96M 10-Q · filed 2025-08-14 | -$43.01M 10-Q · filed 2025-08-14 | -$61.96M derived: sum of 3 quarters · filed 2025-08-14 | -$90.56M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$20.04M 10-Q · filed 2025-05-01 | -$38.99M derived: sum of 2 quarters · filed 2025-05-01 | -$67.59M derived: sum of 3 quarters · filed 2025-05-01 | -$90.34M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | -$18.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$47.55M derived: sum of 2 quarters · filed 2025-03-27 | -$70.30M derived: sum of 3 quarters · filed 2025-03-27 | -$91.96M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$28.60M 10-Q · filed 2024-11-14 | -$51.34M derived: sum of 2 quarters · filed 2024-11-14 | -$73.01M 10-Q · filed 2024-11-14 | -$99.28M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$22.75M 10-Q · filed 2024-08-01 | -$44.41M 10-Q · filed 2024-08-01 | -$70.68M derived: sum of 3 quarters · filed 2024-08-01 | -$95.91M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | -$21.66M 10-Q · filed 2024-05-02 | -$47.94M derived: sum of 2 quarters · filed 2024-05-02 | -$73.17M derived: sum of 3 quarters · filed 2024-05-02 | -$100.82M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | -$26.28M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$51.51M derived: sum of 2 quarters · filed 2024-02-29 | -$79.16M derived: sum of 3 quarters · filed 2024-02-29 | -$103.33M 10-K · filed 2024-02-29 |
| 2022-09-30 | -$25.23M 10-Q · filed 2023-11-09 | -$52.89M derived: sum of 2 quarters · filed 2023-11-09 | -$77.05M 10-Q · filed 2023-11-09 | -$67.81M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$27.66M 10-Q · filed 2023-08-10 | -$51.82M 10-Q · filed 2023-08-10 | -$42.58M derived: sum of 3 quarters · filed 2023-08-10 | -$60.16M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$24.17M 10-Q · filed 2023-05-09 | -$14.92M derived: sum of 2 quarters · filed 2023-05-09 | -$32.50M derived: sum of 3 quarters · filed 2023-05-09 | -$57.01M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $9.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$8.33M derived: sum of 2 quarters · filed 2023-02-23 | -$32.85M derived: sum of 3 quarters · filed 2023-02-23 | -$45.27M 10-K · filed 2023-02-23 |
| 2021-09-30 | -$17.58M 10-Q · filed 2022-11-09 | -$42.09M derived: sum of 2 quarters · filed 2022-11-09 | -$54.52M 10-Q · filed 2022-11-09 | -$66.53M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$24.51M 10-Q · filed 2022-08-11 | -$36.94M 10-Q · filed 2022-08-11 | -$48.95M derived: sum of 3 quarters · filed 2022-08-11 | -$60.78M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$12.42M 10-Q · filed 2022-05-12 | -$24.43M derived: sum of 2 quarters · filed 2022-05-12 | -$36.27M derived: sum of 3 quarters · filed 2022-05-12 | -$42.59M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$12.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$23.85M derived: sum of 2 quarters · filed 2022-03-15 | -$30.17M derived: sum of 3 quarters · filed 2022-03-15 | -$36.93M 10-K · filed 2022-03-15 |
| 2020-09-30 | -$11.84M 10-Q · filed 2021-11-09 | -$18.16M derived: sum of 2 quarters · filed 2021-11-09 | -$24.92M 10-Q · filed 2021-11-09 | -$32.54M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | -$6.32M 10-Q · filed 2021-08-12 | -$13.08M 10-Q · filed 2021-08-12 | -$20.70M derived: sum of 3 quarters · filed 2021-08-12 | -$28.23M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | -$6.76M 10-Q · filed 2021-05-10 | -$14.38M derived: sum of 2 quarters · filed 2021-05-10 | -$21.91M derived: sum of 3 quarters · filed 2021-05-10 | |
| 2019-12-31 | -$7.62M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | -$15.15M derived: sum of 2 quarters · filed 2021-03-16 | -$25.07M 10-K · filed 2021-03-16 | |
| 2019-09-30 | -$7.53M 10-Q · filed 2020-11-13 | -$17.44M 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |